MedTrace Logo

Salmon Peptide Fraction: Safety and Cardiometabolic Health

NCT05025462 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-03-18

No results posted yet for this study

Summary

The overall goal of this study is to verify the safety of 15g of salmon peptide fraction (SPF), and to test the effects on metabolic syndrome risk factors of two doses of SPF (7.5g and 15g) in overweight-obese men and women. Transcriptomic, metabolomic and metagenomic approaches will be used to study the physiological effects of SPF and to discover the potential mechanism underlying these effects.

Conditions

  • Metabolic Syndrome

Interventions

DIETARY_SUPPLEMENT

Supplement dose 15g/d

Supplementation with 15g/day of SPF or Comparator

DIETARY_SUPPLEMENT

Supplement dose 7.5g/d

Supplementation with 7.5g/d of SPF ou comparator

Sponsors & Collaborators

  • Laval University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-07-26
Completion
2023-07-26

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05025462 on ClinicalTrials.gov